Welcome to CDC Stacks | Updated recommendations for prevention of invasive pneumococcal disease among adults using PPSV23 - 7453 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated recommendations for prevention of invasive pneumococcal disease among adults using PPSV23
  • Published Date:
    September 3, 2010
  • Status:
    current
  • Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(34):1102-6.
Filetype[HTML - ]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    Centers for Disease Control (U.S.). Immunization Practices Advisory Committee. ; National Center for Immunization and Respiratory Diseases (U.S.). Division of Bacterial Disases. ;
  • Description:
    Invasive disease from Streptococcus pneumoniae (pneumococcus) is a major cause of illness and death in the United States, with an estimated 43,500 cases and 5,000 deaths among persons of all ages in 2009. This report provides updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for prevention of invasive pneumococcal disease (IPD) (i.e., bacteremia, meningitis, or infection of other normally sterile sites) through use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) among all adults aged >or=65 years and those adults aged 19-64 years with underlying medical conditions that put them at greater risk for serious pneumococcal infection. The new recommendations include the following changes from 1997 ACIP recommendations: 1) the indications for which PPSV23 vaccination is recommended now include smoking and asthma, and 2) routine use of PPSV23 is no longer recommended for Alaska Natives or American Indians aged <65 years unless they have medical or other indications for PPSV23. ACIP recommendations for revaccination with PPSV23 among the adult patient groups at greatest risk for IPD (i.e., persons with functional or anatomic asplenia and persons with immunocompromising conditions) remain unchanged. ACIP recommendations for prevention of pneumococcal disease among infants and youths aged
  • Supporting Files:
    No Additional Files